Chimerix Inc. CEO Michelle Berrey assured investors of "some ways for us to skin this cat a little more quickly," as the company probes the intriguing efficacy of brincidofovir – often shorthanded to "brinci" – against BK virus, although Wall Street meanwhile clipped shares on word that two phase III trials with the oral nucleotide analog in kidney transplant are stopping.